毛细胞白血病市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按治疗(化疗和靶向治疗)和地理划分

市场快照

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

毛细胞白血病是一种非常罕见的癌症,约占所有白血病的 2%。毛细胞白血病的特征是淋巴细胞不受控制地在骨髓中积累。根据国家罕见疾病组织的数据,美国每年诊断出大约 600-800 例新病例。大多数受影响的人是50岁或以上的男性。早期诊断可以帮助患者延长寿命。近年来,有先进的诊断测试来检测毛细胞白血病。首先也是最重要的诊断测试是完整的血液分析,清楚地表明淋巴细胞的总数,这表明疾病。如果脾脏肿大,医生可以通过体格检查轻松诊断。一项重要的确认测试是实验室测试中血液中存在毛细胞。大多数患者还需要进行骨髓活检以确认。在过去的两三年中,毛细胞白血病的诊断率有所增加,预计这将在预测期内推动市场。

报告范围

根据报告的范围,毛细胞白血病是一种与异常淋巴细胞积聚有关的血癌。毛细胞的过度生产和积累会导致正常血细胞的缺乏。

By Therapy
Chemotherapy
Targeted Therapy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

主要市场趋势

化疗板块预计将在预测期内实现显着增长

根据治疗,分为化疗和靶向治疗。促成化疗部分增长的关键因素是白血病病例的发病率上升。据美国癌​​症协会估计,2019 年约有 22,840 人死于白血病。许多公司正专注于开发治疗毛细胞白血病的突破性产品,以保持其竞争优势并打入新的区域市场。化疗药物,特别是嘌呤类似物,如克拉屈滨和喷司他丁,被认为是大多数毛细胞白血病患者的初始治疗选择。此外,为参与毛细胞白血病相关研究的公司提供的资金增加预计将推动所研究的市场。

Hairy Cell Leukemia Market 1

北美在毛细胞白血病市场占有最大份额

由于高发病率、老年人口的增加和毛细胞白血病治疗的进步,毛 细胞白血病市场在北美地区占有最大份额。根据国家罕见疾病组织的数据,毛细胞白血病是一种罕见的血癌,在美国影响了大约 6,000 人。继北美之后,欧洲和亚太地区紧随其后,因为这些地区存在多元化的患者群体和新兴经济体。

Hairy Cell Leukemia Market 2

竞争格局

毛细胞白血病市场竞争激烈,许多全球参与者都进入了市场。例如——Amgen Inc、AstraZeneca plc、BioGenomics Limited、F. Hoffmann-La Roche Ltd、Incyte Corp、Johnson & Johnson、Merck KGaA、Merck & Co, Inc. 和 Pfizer Inc. 正在全球范围内提供这些产品。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Leukemia Cases

      2. 4.2.2 Increase in Diagnosis Rates

      3. 4.2.3 Growing Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness

      2. 4.3.2 Limited Health Services in Rural Hospitals

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Chemotherapy

      2. 5.1.2 Targeted Therapy

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 AstraZeneca plc

      3. 6.1.3 BioGenomics Limited

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Incyte Corp

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Merck KGaA

      8. 6.1.8 Merck & Co, Inc.

      9. 6.1.9 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Hairy Cell Leukemia Market market is studied from 2018 - 2026.

The Hairy Cell Leukemia Market is growing at a CAGR of 5.0% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

AstraZeneca plc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck KGaA, Pfizer Inc. are the major companies operating in Hairy Cell Leukemia Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!